Immunome, Inc.
- UEI
- CKCHDHNUXTM9
- CAGE
- 4U3X6
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | -$274 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| "covid-19" scalable biosynthetic convalescent plasma (IMM-BCP-001) | ACC Aberdeen Proving Ground | $17,598,323 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A heteropolymer antibody for treatment of serotype b bont | National Institutes of Health | $270,025 |
Quick answers
Is Immunome, Inc. registered in SAM.gov?
Immunome, Inc.'s SAM.gov registration expired on February 27, 2025.
What is Immunome, Inc.'s most recent federal award?
Immunome, Inc.'s most recent federal contract award is "covid-19" scalable biosynthetic convalescent plasma (IMM-BCP-001) (W911QY2090019), from ACC Aberdeen Proving Ground, on July 3, 2020.
On GovTribe
See Immunome, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors